Skip to main content

Table 5 Hematological parameters values at baseline and following 15 weeks of double-blind treatment

From: Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension

 

PS-DHA

Placebo

Variable

Baseline (mean ± SD)

15 weeks

(mean ± SD)

P value1 (within group)

Baseline (mean ± SD)

15 weeks

(mean ± SD)

P value1 (within group)

P value2 (between groups)

White blood cell count (×103/cmm)

6.8 ± 1.8

6.5 ± 1.6

0.083

7.1 ± 2.0

6.7 ± 1.9

0.011*

0.434

Male

6.8 ± 1.7

6.4 ± 1.5

0.020*

7.3 ± 2.3

7.1 ± 2.2

0.298

0.467

Female

6.7 ± 1.9

6.7 ± 1.6

0.829

6.9 ± 1.4

6.3 ± 1.3

0.009*

0.066

Red blood cell count (×106/cmm)

4.6 ± 0.5

4.6 ± 0.5

0.441

4.6 ± 0.4

4.6 ± 0.4

0.332

0.765

Male

4.7 ± 0.5

4.7 ± 0.5

0.544

4.6 ± 0.4

4.6 ± 0.4

0.491

0.925

Female

4.5 ± 0.4

4.4 ± 0.4

0.622

4.5 ± 0.4

4.5 ± 0.4

0.488

0.760

Hematocrit (%)

41.2 ± 4.2

40.7 ± 4.3

0.113

41.6 ± 3.6

40.9 ± 3.6

0.045*

0.504

Male

42.5 ± 4.3

42.1 ± 4.4

0.229

42.6 ± 3.6

42.0 ± 3.4

0.100

0.763

Female

39.8 ± 3.7

39.4 ± 3.8

0.309

40.5 ± 3.2

39.6 ± 3.5

0.193

0.548

Hemoglobin (g/dL)

13.7 ± 1.5

13.7 ± 1.5

0.434

13.7 ± 1.2

13.6 ± 1.2

0.213

0.669

Male

14.3 ± 1.4

14.3 ± 1.3

0.706

14.1 ± 1.2

13.9 ± 1.2

0.181

0.623

Female

13.1 ± 1.4

13.0 ± 1.4

0.481

13.3 ± 1.1

13.2 ± 1.1

0.494

0.856

Platelet count (×103/cmm)

221.5 ± 62.7

226.8 ± 60.5

0.374

226.9 ± 73.7

230.8 ± 68.8

0.347

0.839

Male

200.1 ± 44.5

204.0 ± 44.3

0.479

202.8 ± 58.3

210.0 ± 61.1

0.128

0.648

Female

243.5 ± 71.3

250.2 ± 66.4

0.536

255.4 ± 80.6

255.3 ± 70.4

0.980

0.592

Netrophils (%)

62.8 ± 6.5

62.4 ± 6.4

0.514

63.8 ± 8.7

62.9 ± 8.6

0.207

0.543

Male

65.1 ± 6.0

64.4 ± 5.7

0.390

64.8 ± 9.0

64.8 ± 9.2

0.968

0.569

Female

60.4 ± 6.2

60.5 ± 6.7

0.969

62.6 ± 8.4

60.7 ± 7.5

0.097

0.147

Netrophils Absolute (×109/L)

4.3 ± 1.3

4.1 ± 1.0

0.080

4.5 ± 1.4

4.2 ± 1.4

0.037*

0.579

Male

4.5 ± 1.3

4.1 ± 1.1

0.027*

4.7 ± 1.5

4.6 ± 1.7

0.675

0.265

Female

4.1 ± 1.2

4.0 ± 1.0

0.814

4.4 ± 1.2

3.8 ± 1.0

0.010*

0.046*

Lymphocytes (%)

26.0 ± 6.1

26.1 ± 5.8

0.887

25.8 ± 8.7

26.4 ± 8.1

0.324

0.478

Male

23.8 ± 5.6

24.4 ± 5.1

0.453

24.5 ± 8.8

24.4 ± 8.7

0.893

0.529

Female

28.2 ± 5.8

27.8 ± 6.0

0.447

27.3 ± 8.4

28.8 ± 6.9

0.171

0.116

Lymphocytes Absolute (×109/L)

1.8 ± 0.6

1.7 ± 0.5

0.167

1.9 ± 1.1

1.8 ± 0.8

0.051

0.449

Male

1.6 ± 0.5

1.6 ± 0.4

0.234

1.9 ± 1.4

1.7 ± 1.0

0.115

0.468

Female

1.9 ± 0.6

1.8 ± 0.6

0.458

1.8 ± 0.6

1.8 ± 0.5

0.238

0.819

Monocytes (%)

5.8 ± 1.4

6.0 ± 1.5

0.119

5.6 ± 1.0

5.9 ± 1.4

0.093

0.918

Male

5.9 ± 1.5

6.1 ± 1.4

0.343

5.7 ± 0.9

5.9 ± 1.3

0.299

0.976

Female

5.6 ± 1.4

5.9 ± 1.6

0.220

5.5 ± 1.1

5.8 ± 1.5

0.193

0.895

Monocytes Absolute (×109/L)

0.4 ± 0.1

0.4 ± 0.1

0.731

0.4 ± 0.1

0.4 ± 0.1

0.565

0.516

Male

0.4 ± 0.1

0.4 ± 0.1

0.497

0.4 ± 0.1

0.4 ± 0.1

0.890

0.556

Female

0.4 ± 0.1

0.4 ± 0.1

0.284

0.4 ± 0.1

0.4 ± 0.1

0.359

0.159

Eosinophils (%)

3.0 ± 2.5

3.1 ± 3.3

0.365

2.5 ± 1.6

2.5 ± 1.5

0.844

0.540

Male

2.7 ± 1.5

2.8 ± 2.0

0.535

2.8 ± 1.8

2.7 ± 1.7

0.832

0.533

Female

3.3 ± 3.3

3.5 ± 4.2

0.513

2.2 ± 1.4

2.3 ± 1.2

0.660

0.796

Eosinophils Absolute (×109/L)

0.2 ± 0.3

0.2 ± 0.3

0.853

0.2 ± 0.1

0.2 ± 0.1

0.227

0.400

Male

0.2 ± 0.2

0.2 ± 0.2

0.421

0.2 ± 0.1

0.2 ± 0.1

0.280

0.943

Female

0.2 ± 0.4

0.3 ± 0.5

0.382

0.1 ± 0.1

0.1 ± 0.1

0.513

0.284

Basophils (%)

0.7 ± 0.3

0.6 ± 0.3

0.041*

0.7 ± 0.3

0.6 ± 0.3

0.101

0.684

Male

0.7 ± 0.3

0.6 ± 0.3

0.207

0.6 ± 0.3

0.6 ± 0.3

0.099

0.882

Female

0.8 ± 0.2

0.6 ± 0.3

0.113

0.7 ± 0.4

0.7 ± 0.3

0.515

0.482

Basophils Absolute (×109/L)

0.1 ± 0.0

0.0 ± 0.0

0.006*

0.1 ± 0.0

0.0 ± 0.0

0.019*

0.854

Male

0.1 ± 0.0

0.0 ± 0.0

0.035*

0.1 ± 0.0

0.0 ± 0.0

0.058

0.928

Female

0.1 ± 0.0

0.0 ± 0.0

0.077

0.1 ± 0.0

0.0 ± 0.0

0.174

0.701

Large Unstained Cells (%)

1.7 ± 0.6

1.7 ± 0.5

1.000

1.6 ± 0.6

1.7 ± 0.6

0.162

0.306

Male

1.8 ± 0.6

1.8 ± 0.5

0.616

1.6 ± 0.6

1.6 ± 0.6

0.623

0.483

Female

1.7 ± 0.7

1.7. ± 0.6

0.701

1.7 ± 0.5

1.9 ± 0.6

0.139

0.434

Large Unstained Cells Absolute (×109/L)

0.1 ± 0.0

0.1 ± 0.0

0.652

0.1 ± 0.1

0.1 ± 0.1

0.571

0.948

Male

0.1 ± 0.0

0.1 ± 0.0

0.243

0.1 ± 0.1

0.1 ± 0.1

0.568

0.753

Female

0.1 ± 0.1

0.1 ± 0.0

0.784

0.1 ± 0.0

0.1 ± 0.0

0.847

0.742

MCV (μ3)

90.1 ± 4.1

89.6 ± 4.4

0.133

91.0 ± 4.3

90.1 ± 4.3

0.049*

0.506

Male

90.7 ± 4.4

90.2 ± 4.4

0.204

92.2 ± 4.3

91.4 ± 4.6

0.211

0.780

Female

89.5 ± 3.9

89.1 ± 4.31

0.397

89.6 ± 3.9

88.7 ± 3.6

0.124

0.503

MCH (pg)

30.1 ± 2.1

30.1 ± 1.9

0.850

30.0 ± 1.5

30.0 ± 1.4

0.940

0.861

Male

30.6 ± 2.2

30.7 ± 2.0

0.651

30.4 ± 1.6

30.4 ± 1.5

0.842

0.658

Female

29.5 ± 1.8

29.5 ± 1.8

0.801

29.5 ± 1.1

29.5 ± 1.1

0.910

0.810

MCHC (%)

33.4 ± 1.6

33.6 ± 1.4

0.108

33.0 ± 1.2

33.3 ± 0.9

0.041*

0.673

Male

33.8 ± 1.9

34.1 ± 1.7

0.116

33.0 ± 1.2

33.2 ± 1.1

0.267

0.794

Female

32.9 ± 1.1

33.1 ± 0.9

0.533

32.9 ± 1.1

33.3 ± 0.7

0.061

0.335

  1. 1 Based on two-sided t test for dependent samples. 2 Based on two-sided t test for independent samples
  2. * Statistical significance was not maintained following Bonferonni correction
  3. In the treatment arm, 33 males and 32 females had hematological blood measurements at baseline and endpoint.
  4. In the placebo arm, 33 males and 28 females had hematological blood measurements at baseline and endpoint.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us